A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Leuven, Belgien, 3000
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 0000
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 0000
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Den Russiske Føderation, 119331
- Pfizer Investigational Site
-
St. Petersburg, Den Russiske Føderation, 194100
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B18 7QH
- Pfizer Investigational Site
-
London, Det Forenede Kongerige, EC1V 2PD
- Pfizer Investigational Site
-
-
-
-
-
Makati City, Filippinerne, 1200
- Pfizer Investigational Site
-
Mandaluyong City, Filippinerne, 1500
- Pfizer Investigational Site
-
-
-
-
Florida
-
Pembroke Pines, Florida, Forenede Stater, 33028
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Pfizer Investigational Site
-
-
Nevada
-
Henderson, Nevada, Forenede Stater, 89052
- Pfizer Investigational Site
-
Henderson, Nevada, Forenede Stater, 89074
- Pfizer Investigational Site
-
Las Vegas, Nevada, Forenede Stater, 89148
- Pfizer Investigational Site
-
-
-
-
-
Lille Cedex, Frankrig, 59037
- Pfizer Investigational Site
-
Lyon, Frankrig, 69437
- Pfizer Investigational Site
-
-
Cedex 1
-
Amiens, Cedex 1, Frankrig, 80054
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indien, 500034
- Pfizer Investigational Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380004
- Pfizer Investigational Site
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, Indien, 641 014
- Pfizer Investigational Site
-
-
-
-
-
Catania, Italien, 95123
- Pfizer Investigational Site
-
Milano, Italien, 20162
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Polen, 15-274
- Pfizer Investigational Site
-
Gdansk, Polen, 80-211
- Pfizer Investigational Site
-
Wroclaw, Polen, 50-368
- Pfizer Investigational Site
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Pfizer Investigational Site
-
Lisboa, Portugal, 1649-035
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-019
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-097
- Pfizer Investigational Site
-
Porto, Portugal, 4099-001
- Pfizer Investigational Site
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumænien, 400006
- Pfizer Investigational Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Pfizer Investigational Site
-
-
-
-
-
Bratislava, Slovakiet, 83340
- Pfizer Investigational Site
-
-
-
-
-
Ljubljana, Slovenien, 1000
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Spanien, 28040
- Pfizer Investigational Site
-
Sevilla, Spanien, 41013
- Pfizer Investigational Site
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spanien, 08950
- Pfizer Investigational Site
-
-
-
-
-
Myfair West, Sydafrika, 2109
- Pfizer Investigational Site
-
-
-
-
-
Praha 5, Tjekkiet, 150 06
- Pfizer Investigational Site
-
-
-
-
-
Regenstauf, Tyskland, 93128
- Pfizer Investigational Site
-
Schorndorf, Tyskland, 73614
- Pfizer Investigational Site
-
-
-
-
-
Kharkiv, Ukraine, 61000
- Pfizer Investigational Site
-
Kyiv, Ukraine
- Pfizer Investigational Site
-
Kyiv, Ukraine, 04050
- Pfizer Investigational Site
-
Kyiv, Ukraine, 01135
- Pfizer Investigational Site
-
Odesa, Ukraine, 65061
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria:
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Timolol
|
Timolol 0.5% dosed twice-daily
|
|
Eksperimentel: latanoprost
|
Latanoprost 0.005% ophthalmic solution dosed once-daily
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
Tidsramme: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP, LOCF.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were less than or equal to (≤) 2 millimeters of mercury (mmHg) of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction From Baseline in Mean IOP at Week 1
Tidsramme: Baseline, Week 1
|
Calculated as Baseline IOP minus Week 1 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 1
|
|
Reduction From Baseline in Mean IOP at Week 4
Tidsramme: Baseline, Week 4
|
Calculated as Baseline IOP minus Week 4 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4
|
|
Reduction From Baseline in Mean IOP at Week 12 (Observed)
Tidsramme: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
|
Mean IOP at Baseline
Tidsramme: Baseline
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline
|
|
Mean IOP at Week 1
Tidsramme: Week 1
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 1
|
|
Mean IOP at Week 4
Tidsramme: Week 4
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 4
|
|
Mean IOP at Week 12
Tidsramme: Week 12
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 12
|
|
Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
Tidsramme: Baseline, Week 4, and Week 12
|
Participants with ≥15% IOP reduction from baseline at both Week 4 and Week 12. Calculated as (post baseline IOP minus baseline IOP) divided by IOP, multiplied by 100%.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4, and Week 12
|
|
Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
Tidsramme: Baseline through Week 12
|
An investigator's causality assessment was the determination of whether there existed a reasonable possibility that the investigational product caused or contributed to an adverse event (AE).
If the investigator did not know whether or not investigational product caused the event, then the event was handled as "related to investigational product" for reporting purposes.
|
Baseline through Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Øjensygdomme
- Okulær hypertension
- Grøn stær
- Lægemidlers fysiologiske virkninger
- Adrenerge beta-antagonister
- Adrenerge antagonister
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-arytmimidler
- Antihypertensive midler
- Farmaceutiske løsninger
- Oftalmiske løsninger
- Timolol
- Latanoprost
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- A6111137
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .